We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current AREC market cap is 36.75M. The company's latest EPS is GBP -0.2793 and P/E is -4.30.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Total Revenue | 1.45M | 2.15M | 1.8M | 3.54M | 5.72M |
| Operating Income | -1.57M | -3.43M | -6.44M | -10.7M | -9.17M |
| Net Income | -1.28M | -2.75M | -6.17M | -9.26M | -8.55M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Total Assets | 4.31M | 4.28M | 20.92M | 21.77M | 15.38M |
| Total Liabilities | 1.1M | 3.51M | 2.37M | 4.31M | 5.85M |
| Total Equity | 3.21M | 774k | 18.55M | 17.46M | 9.53M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Operating | -268k | -1.86M | -5.45M | -10.78M | -5.84M |
| Investing | -14k | -49k | -68k | -7.99M | 6.52M |
| Financing | -77k | 1.77M | 20.93M | 5.16M | -180k |
| Market Cap | 36.75M |
| Price to Earnings Ratio | -4.30 |
| Price to Sales Ratio | 6.42 |
| Price to Cash Ratio | 7.22 |
| Price to Book Ratio | 3.86 |
| Dividend Yield | - |
| Shares Outstanding | 30.63M |
| Average Volume (1 week) | 5.39k |
| Average Volume (1 Month) | 25.32k |
| 52 Week Change | -47.83% |
| 52 Week High | 240.00 |
| 52 Week Low | 103.50 |
| Spread (Intraday) | 10 (8%) |
| Company Name | Arecor Therapeutics Plc |
| Address |
chesterford research park london CB10 1XL |
| Website | https://www.arecor.com |
| Industry | coml physical, biologcl resh (8731) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
